0001179110-19-010682.txt : 20190926 0001179110-19-010682.hdr.sgml : 20190926 20190926182244 ACCESSION NUMBER: 0001179110-19-010682 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190925 FILED AS OF DATE: 20190926 DATE AS OF CHANGE: 20190926 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MARINO JAMES J CENTRAL INDEX KEY: 0001198578 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36020 FILM NUMBER: 191119185 MAIL ADDRESS: STREET 1: C/O ONCONOVA THERAPEUTICS STREET 2: 375 PHEASANT RUN CITY: NEWTOWN STATE: PA ZIP: 18940 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Onconova Therapeutics, Inc. CENTRAL INDEX KEY: 0001130598 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 375 PHEASANT RUN CITY: NEWTOWN STATE: PA ZIP: 18940 BUSINESS PHONE: 267-759-3681 MAIL ADDRESS: STREET 1: 375 PHEASANT RUN CITY: NEWTOWN STATE: PA ZIP: 18940 FORMER COMPANY: FORMER CONFORMED NAME: ONCONOVA THERAPEUTICS, INC. DATE OF NAME CHANGE: 20090526 FORMER COMPANY: FORMER CONFORMED NAME: ONCONOVA THERAPEUTICS INC DATE OF NAME CHANGE: 20001226 4 1 edgar.xml FORM 4 - X0306 4 2019-09-25 0 0001130598 Onconova Therapeutics, Inc. ONTX 0001198578 MARINO JAMES J C/O ONCONOVA THERAPEUTICS 375 PHEASANT RUN NEWTOWN PA 18940 1 0 0 0 Common Stock 2019-09-25 4 P 0 7260 1.60 A 16942 D Warrant (right to purchase) 1.01 2019-09-25 4 H 0 5000 D 2018-02-12 Series A Convertible Preferred Stock 5000 0 D Warrant (right to purchase) .1067 2019-09-25 4 P 0 5000 A 2019-09-25 2022-12-31 Series A Convertible Preferred Stock 5000 5000 D Warrant (right to purchase) .425 2019-09-25 4 H 0 1472.5 D 2018-05-01 Series B Convertible Preferred Stock 1472.5 0 D Warrant (right to purchase) .1067 2019-09-25 4 P 0 1472.5 A 2019-09-25 2022-12-31 Series B Convertible Preferred Stock 1472.5 1472.5 D These warrants were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $1.01. The warrants were exercisable immediately at an exercise price of $1.01 per 0.1 share of Series A Convertible Preferred Stock and would expire on the later of (i) the one-year anniversary of the date on which theCompany publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which the Company publically releases certain topline results of the INSPIRE Pivotal phase 3 trial that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019. In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock). These warrants were acquired in a public offering, by the Company, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The warrants were exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and would expire on the 18-month anniversary of the date on which the Company publicly announced through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware. In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock). /s/ Mark Guerin as attorney-in-fact 2019-09-26